Revision as of 20:12, 10 August 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'UNII').← Previous edit | Revision as of 20:23, 10 August 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/ChemNext edit → | ||
Line 1: | Line 1: | ||
{{Drugbox| verifiedrevid = |
{{Drugbox| verifiedrevid = 444128206 | ||
| | | | ||
|IUPAC_name = ''N''-oct-3-yl]-1-benzofuran-2-carboxamide | |IUPAC_name = ''N''-oct-3-yl]-1-benzofuran-2-carboxamide | ||
Line 7: | Line 7: | ||
| ATC_prefix= | | ATC_prefix= | ||
| ATC_suffix= | | ATC_suffix= | ||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = UM3821998K | | UNII = UM3821998K | ||
| PubChem= 16727410 | | PubChem= 16727410 | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank= | | DrugBank= | ||
| C=22 | H=23 | N=3 | O=2 | | C=22 | H=23 | N=3 | O=2 |
Revision as of 20:23, 10 August 2011
Pharmaceutical compoundFile:TC-5619.png | |
Identifiers | |
---|---|
IUPAC name
| |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H23N3O2 |
Molar mass | 361.437 g·mol |
3D model (JSmol) | |
SMILES
| |
(verify) |
TC-5619 is a drug developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia. Phase I clinical trials have been completed successfully, and it is currently in Phase II trials.
In May 2011, AstraZeneca declined to exercise its right to license the compound.
References
- TC-5619 Cognitive Dysfunction in Schizophrenia
- Rethinking Schizophrenia
- Targacept retains full development rights for TC-5619